close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

17.57 -0.42 (-2.33%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,591,109
Open 17.97
Bid (Size) 17.58 (800)
Ask (Size) 17.90 (100)
Prev. Close 17.99
Today's Range 17.39 - 18.02
52wk Range 15.55 - 36.91
Shares Outstanding 97,381,774
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth
As 2025 draws to a close, a powerful undercurrent of technological innovation, extending far beyond the pervasive influence of artificial intelligence, is demonstrably reshaping the global stock... 
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
News headline image
Up Nearly 400% This Year, Can Oklo Stock Still Rise Higher? ↗
Many investors see this nuclear power company as a possible answer to the growing energy needs from artificial intelligence, and it has benefited from that. 
Via The Motley Fool
Topics Artificial Intelligence

Performance

YTD
-4.3%
-4.3%
1 Month
-6.7%
-6.7%
3 Month
-7.2%
-7.2%
6 Month
-11.2%
-11.2%
1 Year
-1.7%
-1.7%

More News

Read More
Summit Therapeutics Stock Sparks Retail Buzz After Ivonescimab Combo Cuts Cancer Progression Risk By 40% ↗
Via Stocktwits
News headline image
An Overview of Summit Therapeutics's Earnings ↗
Via Benzinga
News headline image
2 Stocks Up Over 600% in the Past 3 Years With More Room to Run ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics
Via Business Wire
News headline image
Trading Near Its 52-Week Low, Is Summit Therapeutics a Good Stock to Buy Right Now? ↗
Via The Motley Fool
News headline image
Don't Buy Summit Therapeutics Until This Big Thing Happen ↗
Via The Motley Fool
News headline image
2 Monster Stocks in the Making to Buy and Hold ↗
Via The Motley Fool
News headline image
Summit SMMT Q3 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China
From Summit Therapeutics
Via Business Wire
News headline image
Summit Therapeutics to Present at Upcoming Investor Conferences
From Summit Therapeutics
Via Business Wire
News headline image
Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025
From Summit Therapeutics
Via Business Wire
News headline image
Alpha Buying: When Insiders Buy Big & Why It Works in Every Market ↗
Via Benzinga
News headline image
Why Wall Street Is Backing These 3 Comeback Stocks ↗
Via MarketBeat
News headline image
1 Monster Stock in the Making to Buy and Hold ↗
Via The Motley Fool
News headline image
Summit Therapeutics: A Risky Bet in the Biotech Arena? ↗
Via The Motley Fool
News headline image
Summit Therapeutics Raises $500 Million in Private Placement
From Summit Therapeutics
Via Business Wire
News headline image
What's Going On With Summit Therapeutics Stock On Monday? ↗
Via Benzinga
News headline image
Retail Investors' Top Stocks With Earnings This Week: Tesla, Netflix, Intel and More ↗
Via Benzinga
News headline image
Summit Therapeutics Inc (NASDAQ:SMMT) Reports Wider-Than-Expected Q3 2025 Loss ↗
Via Chartmill
News headline image
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025
From Summit Therapeutics
Via Business Wire
News headline image
Earnings Scheduled For October 20, 2025 ↗
Via Benzinga
News headline image
Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
From Summit Therapeutics
Via Business Wire
News headline image
Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer
From Summit Therapeutics
Via Business Wire

Frequently Asked Questions

Is Summit Therapeutics Inc. - Common Stock publicly traded?
Yes, Summit Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Summit Therapeutics Inc. - Common Stock trade on?
Summit Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Summit Therapeutics Inc. - Common Stock?
The ticker symbol for Summit Therapeutics Inc. - Common Stock is SMMT on the Nasdaq Stock Market
What is the current price of Summit Therapeutics Inc. - Common Stock?
The current price of Summit Therapeutics Inc. - Common Stock is 17.57
When was Summit Therapeutics Inc. - Common Stock last traded?
The last trade of Summit Therapeutics Inc. - Common Stock was at 12/12/25 04:00 PM ET
What is the market capitalization of Summit Therapeutics Inc. - Common Stock?
The market capitalization of Summit Therapeutics Inc. - Common Stock is 1.71B
How many shares of Summit Therapeutics Inc. - Common Stock are outstanding?
Summit Therapeutics Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today